Endo And Mallinckrodt Plan To Merge - And Spin Off Generics Business

CEO Siggi Olafsson Will Lead The Combined Firm

 
• By Joseph Haas

Both vexed by bankruptcies and opioid litigation, Endo and Mallinckrodt will merge in a deal valued at $6.7bn. The new company will spin out its generics and sterile injectable business.

Company merger
The Endo/Mallinckrodt combination is valued at an estimated $6.7bn • Source: Shutterstock

More from Deals

More from Products